Grožio injekcija, MB - financials and debts

Company age: 6 y. 7 mo.

Update

Grožio injekcija - Company finances

EUR
2020
From: 2020-02-24
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 300 - - - 5,912 9,966
Profit before tax 215 -707 -696 -766 502 1,064
Net profit 215 -707 -696 -766 477 1,000
Equity 215 -491 -1,186 -1,952 -1,476 -475
Liabilities 85 488 1,185 1,952 2,565 2,999
Non-current assets 0 0 0 0 364 267
Current assets 300 -3 -1 0 725 2,257
Total assets 300 -3 -1 0 1,089 2,524
Taxes paid
STI taxes - - - - - 25
Financial indicators
Revenue change y/y - - - - - +68.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 71.7% - - - 43.8% 39.6%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 100.0% - - - - -
Profit margin Net profit margin. Shows the overall profitability of the company. 71.7% - - - 8.1% 10.0%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 71.7% - - - 8.5% 10.7%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.4 - - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Grožio injekcija - Social security debts

From To Debt, €
2026-05-06 2026-05-31 1262.25
2025-12-02 2025-12-31 13.82
2024-05-15 2024-06-30 423.97
2024-05-06 2024-05-14 70.37
2024-05-02 2024-05-05 129.00
2024-04-11 2024-05-01 64.50
2024-04-03 2024-04-10 652.70
2024-03-01 2024-04-02 588.20
2024-02-01 2024-02-29 523.70
2024-01-03 2024-01-31 459.20
2023-12-01 2024-01-02 400.57
2023-11-03 2023-11-30 341.94
2023-10-03 2023-11-02 283.31
2023-09-18 2023-10-02 224.68
2023-09-01 2023-09-17 234.52
2023-08-01 2023-08-31 175.89
2023-07-03 2023-07-31 117.26
2023-05-02 2023-07-02 58.63
2023-04-11 2023-04-30 58.63
2023-04-03 2023-04-10 88.29
2023-03-31 2023-04-02 29.66
2023-02-21 2023-03-30 58.63
2023-02-01 2023-02-20 160.53
2023-01-03 2023-01-31 101.90
2022-12-01 2023-01-02 50.95
2022-11-11 2022-11-30 48.60
2022-11-03 2022-11-10 50.95
2022-10-25 2022-11-02 49.37
2022-10-24 2022-10-24 50.95
2022-10-03 2022-10-23 101.90
2022-09-05 2022-10-02 50.95
2022-09-01 2022-09-04 111.75
2022-08-31 2022-08-31 60.80
2022-08-02 2022-08-30 101.90
2022-06-07 2022-08-01 50.95
2022-06-01 2022-06-06 106.52
2022-05-03 2022-05-31 55.57
2022-04-08 2022-05-02 4.62
2022-04-01 2022-04-07 50.95
2022-03-08 2022-03-31 10.39
2022-03-07 2022-03-07 50.95
2022-03-01 2022-03-06 56.11
2022-02-09 2022-02-28 5.16
2022-02-01 2022-02-08 50.95
2022-01-03 2022-01-31 134.43
2021-12-01 2021-12-31 89.62
2021-11-04 2021-11-30 44.81
2021-10-01 2021-10-31 44.81
2021-09-01 2021-09-30 89.62

Grožio injekcija - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Grožio injekcija, MB (code 305480061) is a Small partnership engaged in retail sale of cosmetic and toilet articles. In the latest financial year, 2025, the company generated revenue of EUR 10.0K, up 68.6% year on year from EUR 5.9K in 2024. Net profit increased to EUR 1.0K in 2025 from EUR 477 in 2024, following a net loss of EUR 766 in 2023. Profitability remained positive and improved slightly, with a net profit margin of 10.0% in 2025 versus 8.1% in 2024. The balance sheet also strengthened during the year: total assets rose to EUR 2.5K from EUR 1.1K, driven mainly by short-term assets of EUR 2.3K, while long-term assets were EUR 267. Equity remained negative but improved to EUR -475 from EUR -1.5K, and liabilities increased to EUR 3.0K from EUR 2.6K. Return on assets was 39.6% in 2025, reflecting higher earnings relative to the asset base, while the negative equity position limits the usefulness of return on equity and leverage ratios.